Serotonin 5-HT2 receptor imaging in major depression: Focal changes in orbito-insular cortex

Department of Psychiatry, Erasme Hospital, Brussels, Beligum.
The British Journal of Psychiatry (Impact Factor: 7.34). 12/1997; 171:444-8.
Source: PubMed

ABSTRACT Serotonin receptors may play an important role in the pathophysiology of affective disorders. We studied type-2 serotonin (5-HT2) receptors in the brain of patients with major depression.
Using positron emission tomography (PET) and the selective radioligand [18F]altanserin, we investigated 5-HT2 receptor distribution in eight drug-free unipolar depressed patients and 22 healthy subjects. Data were analysed using Statistical Parametric Mapping 95.
In depressed patients, [18F]altanserin uptake was significantly reduced in a region of the right hemisphere including the posterolateral orbitofrontal cortex and the anterior insular cortex. A trend to similar changes was found in the left hemisphere. No correlation was found between the uptake and the Hamilton rating scale score.
Pathophysiology of depression may involve changes in 5-HT2 receptor in brain regions selectively implicated in mood regulation.

Download full-text


Available from: Serge Goldman, Jan 14, 2014
  • Source
    • "Imaging studies of pre-and post-synaptic 5-HT receptors have also shown decreased 5-HT 2 (Meyer et al., 1999; Yatham et al., 1999) and 5-HT 2A receptor binding (Biver et al., 1997; Massou et al., 1997) in depressed patients compared to non-depressed ones, although these findings are not universally observed (D'haenen et al., 1992). While studies of SERT binding in depression have been attempted using 11 C and 18 F-labeled fluoxetine, sertraline, citalopram and paroxetine (Dannals et al., 1990; Suehiro et al., 1991; Das and Mukherjee, 1993), these agents were not suitable for imaging in humans (Scheffel et al., 1994). "
    [Show abstract] [Hide abstract]
    ABSTRACT: We examined midbrain, medial temporal lobe, and basal ganglia serotonin transporter (SERT) distribution volume ratio (DVR) values in subjects with major depressive disorder versus healthy volunteers using a selective SERT radioligand and single photon emission computed tomography (SPECT). We hypothesized that the DVR value for SERT binding would be lower in depressed versus non-depressed subjects. [(123)I]-ADAM SPECT scans were acquired from 20 drug free, depressed subjects and 20 drug-free depressed subjects and 10 drug-free healthy volunteers. The primary outcome measure was the DVR value for [(123)I]-ADAM uptake in the midbrain, medial temporal lobe, and basal ganglia regions. Depressed subjects demonstrated significantly lower DVR values in the midbrain, right and left medial temporal lobe, and right and left basal ganglia. There was significant probability that lower DVR values could distinguish between depressed and non-depressed subjects in the midbrain, medial temporal lobe, and the right and left basal ganglia. These findings confirm prior observations of lower SERT binding in depression, and suggest that low SERT binding may represent a putative biomarker of depression. Future studies are needed to confirm these observations.
    Psychiatry Research 06/2012; 202(2):161-7. DOI:10.1016/j.pscychresns.2011.12.015 · 2.68 Impact Factor
  • Source
    • "We have been studying the central serotonin-2A receptor (5HT 2A ) and its relationship to suicidal behavior in Borderline Personality Disorder, a diagnostic group at high risk for impulsive-aggression, suicide attempts and completion (Soloff, 2007). Dysregulation of central 5HT 2A receptor function has been demonstrated in patients with major depressive disorder (MDD) (Biver, 1997; Yatham, 2000; Messa, 2003; Meyer, 2003; Mintun, 2004; Bhagwagar, 2006), borderline personality disorder (BPD) (Soloff, 2007), and among subjects with attempted or completed suicide (van Heeringen, 2003; Audenaert, 2000; Rosel, 1998, 2000; Arango, 1995, 1997). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The vulnerability to mood disorders, impulsive-aggression, eating disorders, and suicidal behavior varies greatly with gender, and may reflect gender differences in central serotonergic function. We investigated the relationships of gender, mood, impulsivity, aggression and temperament to 5HT(2A) receptor binding in 21 healthy subjects using [18F]altanserin and PET neuroimaging. Binding potentials in pre-defined regions-of-interest (ROI) were calculated using the Logan graphical method, corrected for partial volume effects, and compared by gender with age co-varied. SPM analysis was used for voxel level comparisons. Altanserin binding (BP(P)) was greater in male than female subjects in the following nine ROIs: hippocampus (HIP) and Lt. HIP, lateral orbital frontal cortex (LOF) and Lt. LOF, left medial frontal cortex (Lt. MFC), left medial temporal cortex (Lt. MTC), left occipital cortex (Lt. OCC), thalamus (THL) and Lt. THL. Differences in Lt. HIP and Lt. MTL remained significant after Bonferroni correction. Gender differences were noted in the co-variation of psychological traits with BP(P) values in specific ROIs. Among males alone, aggression was negatively correlated with BP(P) values in Lt. LOF and Lt. MFC, and Suspiciousness positively correlated in LOF, Lt. LOF and Lt. MFC. Among female subjects alone, Negativism was positively correlated with BP(P) values in HIP, and Verbal Hostility in Lt. HIP. Altanserin binding in Lt. MTC was positively correlated with Persistence, with no significant gender effect. Gender differences in 5HT(2A) receptor function in specific ROIs may mediate expression of psychological characteristics such as aggression, suspiciousness and negativism. Future studies of 5HT(2A) receptor function and its relationship to behavior should control for gender.
    Psychiatry Research 12/2009; 181(1):77-84. DOI:10.1016/j.pscychresns.2009.08.007 · 2.68 Impact Factor
  • Source
    • "Multiple lines of evidence have implicated the role of serotonin in suicidal behavior. These include decreased levels of 5-HIAA in the CSF of suicide victims or attempters(Asberg et al. 1976;Roy et al. 1989), altered expression of HTR2A receptors in suicide and affective illness(Arango et al. 1990;Biver et al. 1997;Mann et al. 1986;Yatham et al. 2000), and the mechanism of antidepressant medications, especially SSRIs, which decrease the reuptake of serotonin, and the use of which has been associated with decreased rates of suicide(Olfson et al. 2003;Gibbons et al. 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Genetic variation in the serotonin 2A receptor (HTR2A) has been associated with both schizophrenia and suicidal behavior. Our sample comprised 270 Irish high-density schizophrenia families (n = 1,408 subjects, including 755 with psychotic illness). Diagnoses were generated using a modified SCID. All patients who had at least one episode of psychosis were rated on the Operation Criteria Checklist for Psychotic Illness (OPCRIT). Lifetime history of suicidal ideation was determined from medical records and psychiatric interviews and was scored in the OPCRIT. Twelve SNPs were selected for study. Ten of these were tagSNPs derived from HapMap data, along with His452Tyr and T102C. We tested for association with psychotic illness as a whole, as well as stratified by the presence of suicidal ideation, using FBAT and PDTPHASE. Single-marker as well as haplotype-based tests using a "sliding window" approach were performed. We observed several 2, 3, and 4 marker haplotypes near the 3' end of the gene that were over-transmitted to psychotic subjects (0.02 </= P </= 0.04). His452Tyr was included in these haplotypes but was not itself significant. We also observed modest over-transmission of a 2-marker haplotype that included T102C (0.04 </= P </= 0.08), which was also not itself significant in single-marker analyses. There was no significant association in the subgroup of the sample with suicidal ideation. Because of multiple testing, these results do not provide support for HTR2A as a susceptibility gene for psychotic illness, or for suicidal ideation within psychotic illness.
    American Journal of Medical Genetics Part B Neuropsychiatric Genetics 04/2009; 150B(3):411-7. DOI:10.1002/ajmg.b.30833 · 3.27 Impact Factor
Show more